1385 related articles for article (PubMed ID: 22341567)
21. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
[TBL] [Abstract][Full Text] [Related]
23. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
24. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
27. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
Melichar B; Studentová H; Zezulová M
J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
[TBL] [Abstract][Full Text] [Related]
28. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
McCormack PL
Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib: in advanced renal cell carcinoma.
Sanford M; Keating GM
BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
32. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
36. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
37. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
Matrana MR; Baiomy A; Campbell M; Alamri S; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Elsayes KM; Tannir NM
Clin Genitourin Cancer; 2017 Apr; 15(2):e205-e208. PubMed ID: 27568124
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
